Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
9.0
6.0
Journals
Cells
Special Issues
Osteosarcoma: From Molecular Mechanisms to Therapeutic Opportunities
share announcement

Osteosarcoma: From Molecular Mechanisms to Therapeutic Opportunities

A special issue of Cells (ISSN 2073-4409). This special issue belongs to the section "Cellular Pathology".

Deadline for manuscript submissions: closed (15 February 2022) | Viewed by 3736

Special Issue Editor

Dr. Frédéric Lézot

E-Mail Website
Guest Editor
Sorbone Université, INSERM UMR933, Hôpital Armand Trousseau (AP-HP), F-75012 Paris, France
Interests: skeleton growth defects; primary bone tumors; bone microenvironment; pathophysiology
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

I am very pleased to announce the inaugural Special Issue in the journal Cells with the title of “Osteosarcoma from Molecular Mechanisms to Therapeutic Opportunities”. This Special Issue devoted to osteosarcoma will serve as a platform for you to publish your last original data or review manuscripts regarding therapeutic opportunities deriving from research on the various molecular mechanisms supporting osteosarcoma growth, metastatic dissemination, and/or resistance to conventional therapies. All molecular mechanisms will be considered, from classical cytokines and growth factor pathway disruptions to epigenetic factors and regulatory RNAs (lncRNA, CircRNA and miRNA), including metabolism, cell cycle, endocrine, paracrine, and immune ones. Molecular mechanisms directly concerning the tumor cell as well as those in cells of the microenvironment are of interest, as are data on molecular mechanisms associated to less conventional therapies for osteosarcoma, such as radiotherapy, cryotherapy, immunotherapy, considering a clear link to therapeutic opportunities. Finally, research devoted to molecular mechanisms specific to either pediatric or adult osteosarcomas is encouraged as an age-related etiology is suspected for osteosarcomas.

We look forward to receiving your manuscripts.

Dr. Frédéric Lézot
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cells is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • osteosarcoma
  • molecular mechanisms
  • tumor growth
  • metastatic dissemination
  • resistance
  • therapy

Published Papers (1 paper)

Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

13 pages, 1683 KiB  
Article
Extracellular Vesicle-Mediated IL-1 Signaling in Response to Doxorubicin Activates PD-L1 Expression in Osteosarcoma Models
by Su Yati, Atiruj Silathapanasakul, Chakrarin Thakaeng, Mayuree Chanasakulniyom, Napat Songtawee, Sureerut Porntadavity, Peraphan Pothacharoen, Dumnoensun Pruksakorn, Prachya Kongtawelert, Pa-thai Yenchitsomanus and Theerawut Chanmee
Cells 2022, 11(6), 1042; https://0-doi-org.brum.beds.ac.uk/10.3390/cells11061042 - 18 Mar 2022
Cited by 11 | Viewed by 3177
Abstract
The expression of programmed cell death ligand 1 (PD-L1) in tumors is associated with tumor cell escape from T-cell cytotoxicity, and is considered a crucial effector in chemoresistance and tumor relapse. Although PD-L1 induction has been observed in patients after chemotherapy treatment, the [...] Read more.
The expression of programmed cell death ligand 1 (PD-L1) in tumors is associated with tumor cell escape from T-cell cytotoxicity, and is considered a crucial effector in chemoresistance and tumor relapse. Although PD-L1 induction has been observed in patients after chemotherapy treatment, the mechanism by which the drug activates PD-L1 expression remains elusive. Here, we identified the extracellular vesicles (EVs) as a molecular mediator that determines the effect of doxorubicin on PD-L1 expression in osteosarcoma models. Mechanistically, doxorubicin dependently stimulates the release of extracellular vesicles, which mediate autocrine/paracrine signals in osteosarcoma cells. The recipient cells were stimulated by these EVs and acquired the ability to promote the expression of inflammatory cytokines interleukin (IL)-1β and IL-6. In response to doxorubicin, IL-1β, but not IL-6, allowed- osteosarcoma cells to promote the expression of PD-L1, and the elimination of IL-1β/IL-1 receptor signaling with IL-1 receptor antagonist reduced PD-L1 expression. Together, these findings provided insights into the role of EV release in response to chemotherapy that mediates PD-L1 expression via the IL-1 signaling pathway, and suggested that the combination of a drug targeting IL-1 or PD-L1 with chemotherapy could be an effective treatment option for osteosarcoma patients. Full article
(This article belongs to the Special Issue Osteosarcoma: From Molecular Mechanisms to Therapeutic Opportunities)
►▼ Show Figures

Graphical abstract

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-1
Back to TopTop